Elevated miR-214-3p expression in osteoclasts, which was observed in bone tissues of breast cancer patients with OBM and corroborated in osteoclasts from breast cancer xenograft (BCX) models, directly targets TRAF3 to suppress its expression, thereby enhancing osteoclast differentiation and bone-resorbing activity that drives OBM progression (Liu et al., 2017). This evidence concerns the gene TRAF3 and breast carcinoma.